Rituximab: A new therapeutic tool for primary immune thrombocytopenic purpura?

Haematologica

Volumn 88, Issue 5, 2003, Pages 482-484

  Introna, Martino ^a   Golay, Josée ^a   Barbui, Tiziano ^b  

^a Molec Immunohaematology Laboratory   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD20 ANTIGEN; FC RECEPTOR; FIBRINOGEN RECEPTOR; MONOCLONAL ANTIBODY; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; CORRELATION ANALYSIS; DRUG MECHANISM; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NOTE; PATHOGENESIS; PHAGOCYTOSIS; RECEPTOR BINDING; THROMBOCYTE COUNT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; HUMANS; LYMPHOCYTE DEPLETION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 0038100526     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (12)

1. Harrington WJ, Minnich V, Ollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951;38:1-10.
2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1007.
3. Berchtold P, Muller D, Beardsley D, Fujisawa K, Kaplan C, Kekomaki R, et al. International study to compare antigenspecific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol 1997;96:477-83.
4. Zaja F, Vianelli N, Sperotto A, De Vita S, Iatona I, Zaccaria A, et al. The B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003;88:538-46.
5. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29 Suppl 2:2-9.
6. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001;98:3383-9.
7. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to antiCD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95:3900-8.
8. Golay J, Gramigna R, Facchinetti V, Capello D, Gaidano G, Introna M. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. Br J Haematol 2002;119:923-9.
9. Introna M, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. Blood 2002;100 Suppl 1:161a[abstract].
10. Hedge UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002; 100:2260-2.
11. Van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115: 807-11.
12. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune disease. N Engl J Med 1999;340:227-8.